Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions

Fatemeh Talebian, Jin Qing Liu, Zhenzhen Liu, Mazin Khattabi, Yukai He, Ramesh Ganju, Xue Feng Bai

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

CD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1 -/-C57BL/6 mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs of both C57BL/6 and Rag1 -/-C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1 + myeloid cells in the lung than in peripheral myeloid cells. Depletion of Gr1 + cells or stimulation of CD200R with an agonistic antibody in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.

Original languageEnglish (US)
Article numbere31442
JournalPloS one
Volume7
Issue number2
DOIs
StatePublished - Feb 3 2012

Fingerprint

Myeloid Cells
melanoma
metastasis
Tumors
Melanoma
lungs
Cells
Neoplasm Metastasis
Lung
neoplasms
Bearings (structural)
Neoplasms
Experimental Melanomas
cells
mice
Inbred C57BL Mouse
T-cells
Flow cytometry
Membrane Glycoproteins
Neoplasm Antigens

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)

Cite this

Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. / Talebian, Fatemeh; Liu, Jin Qing; Liu, Zhenzhen; Khattabi, Mazin; He, Yukai; Ganju, Ramesh; Bai, Xue Feng.

In: PloS one, Vol. 7, No. 2, e31442, 03.02.2012.

Research output: Contribution to journalArticle

Talebian, Fatemeh ; Liu, Jin Qing ; Liu, Zhenzhen ; Khattabi, Mazin ; He, Yukai ; Ganju, Ramesh ; Bai, Xue Feng. / Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. In: PloS one. 2012 ; Vol. 7, No. 2.
@article{98a6d75cc29841cfbf3bd8f542e2628b,
title = "Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions",
abstract = "CD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1 -/-C57BL/6 mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs of both C57BL/6 and Rag1 -/-C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1 + myeloid cells in the lung than in peripheral myeloid cells. Depletion of Gr1 + cells or stimulation of CD200R with an agonistic antibody in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.",
author = "Fatemeh Talebian and Liu, {Jin Qing} and Zhenzhen Liu and Mazin Khattabi and Yukai He and Ramesh Ganju and Bai, {Xue Feng}",
year = "2012",
month = "2",
day = "3",
doi = "10.1371/journal.pone.0031442",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions

AU - Talebian, Fatemeh

AU - Liu, Jin Qing

AU - Liu, Zhenzhen

AU - Khattabi, Mazin

AU - He, Yukai

AU - Ganju, Ramesh

AU - Bai, Xue Feng

PY - 2012/2/3

Y1 - 2012/2/3

N2 - CD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1 -/-C57BL/6 mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs of both C57BL/6 and Rag1 -/-C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1 + myeloid cells in the lung than in peripheral myeloid cells. Depletion of Gr1 + cells or stimulation of CD200R with an agonistic antibody in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.

AB - CD200 is a cell surface glycoprotein that functions through engaging CD200 receptor on cells of the myeloid lineage and inhibits their functions. Expression of CD200 has been implicated in a variety of human cancer cells including melanoma cells and has been thought to play a protumor role. To investigate the role of cancer cell expression of CD200 in tumor formation and metastasis, we generated CD200-positive and CD200-negative B16 melanoma cells. Subcutaneous injection of CD200-positive B16 melanoma cells inhibited tumor formation and growth in C57BL/6 mice but not in Rag1 -/-C57BL/6 mice. However, i.v. injection of CD200-positive B16 melanoma cells dramatically inhibited tumor foci formation in the lungs of both C57BL/6 and Rag1 -/-C57BL6 mice. Flow cytometry analysis revealed higher expression of CD200R in Gr1 + myeloid cells in the lung than in peripheral myeloid cells. Depletion of Gr1 + cells or stimulation of CD200R with an agonistic antibody in vivo dramatically inhibited tumor foci formation in the lungs. In addition, treatment with tumor antigen specific CD4 or CD8 T cells or their combination yielded a survival advantage for CD200 positive tumor bearing mice over mice bearing CD200-negative tumors. Taken together, we have revealed a novel role for CD200-CD200R interaction in inhibiting tumor formation and metastasis. Targeting CD200R may represent a novel approach for cancer immunotherapy.

UR - http://www.scopus.com/inward/record.url?scp=84863062056&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863062056&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0031442

DO - 10.1371/journal.pone.0031442

M3 - Article

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e31442

ER -